MiNK Therapeutics (NASDAQ:INKT) unveiled new translational data at the Keystone Symposia on Wednesday, providing the first direct evidence in humans that a specific immune cell deficiency may be a primary driver of the scarring that defines idiopathic pulmonary fibrosis (IPF).
GSK (NYSE:GSK) reported fourth-quarter results that cleared Wall Street estimates, as the British drugmaker successfully leveraged its high-growth specialty medicines to offset slowing demand for its flagship RSV vaccine, Arexvy.
Novartis (NYSE:NVS) reported fourth-quarter adjusted earnings that beat analyst estimates on Wednesday, but the Swiss pharmaceutical giant issued a cautious 2026 outlook as it prepares to navigate the largest wave of patent expirations in its history.
Novo Nordisk (NYSE:NVO) reported fourth-quarter results on Wednesday that exceeded analyst expectations, but shares plummeted as the Danish pharmaceutical giant issued a "shocking" outlook for 2026, warning of a potential double-digit decline in sales and profit.
Mesa Laboratories (NASDAQ:MLAB) reported a sharp increase in profitability for its third fiscal quarter, as strong demand for its biopharmaceutical tools more than offset a collapse in its Chinese diagnostic business.
National Research Corporation (NASDAQ:NRC), the experience-improvement firm known as NRC Health, reported fourth-quarter results that signaled a steady operational turnaround, bolstered by a fifth consecutive quarter of growth in its core recurring contract base.
Pfizer (NYSE:PFE) announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its fully-biased, ultra-long-acting injectable GLP-1 receptor agonist PF’3944 (nexiguran ziclumeran) in adults with obesity or overweight without type 2 diabetes.
Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, February 3, 2026, signaling a definitive shift away from its pandemic-era reliance.
Merck (NYSE:MRK) today reported fourth-quarter and full-year 2025 results that showcased a tale of two portfolios: a surging oncology and respiratory business set against a dramatic collapse in vaccine demand from China.
Vertex Pharmaceuticals (NASDAQ:VRTX) and WuXi Biologics announced a major license and research service agreement on Monday, February 2, 2026, aimed at developing an innovative trispecific T-cell Engager (TCE) for B-cell mediated autoimmune diseases.
Leiden, Netherlands-based Pharming Group (NASDAQ:PHARM) provided 2026 financial guidance and detailed its rare disease pipeline at its Investor Day on February 3, 2026.
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan), a TROP2-directed antibody-drug conjugate (ADC).
